Adamas Announces Proposed Public Offering of Common Stock
January 05 2016 - 7:15AM
Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced that it
plans to offer 2,500,000 shares of its common stock in an
underwritten public offering. Adamas expects to grant the
underwriters a 30-day option to acquire an additional 375,000
shares. The offering is subject to market and other conditions, and
there can be no assurance as to whether or when the offering may be
completed, or as to the actual size or terms of the offering.
Cowen and Company, LLC and Piper Jaffray & Co. are acting as
book-running managers for the proposed offering, with William Blair
& Company, L.L.C., JMP Securities LLC and Trout Capital LLC
acting as co-managers.
A shelf registration statement relating to the shares was filed
with the Securities and Exchange Commission on May 18, 2015, and
became effective on June 1, 2015. The offering will be made only by
means of a prospectus supplement. When available, copies of the
preliminary prospectus supplement and accompanying prospectus
relating to the proposed public offering may be obtained by
contacting Cowen and Company, LLC, c/o Broadridge Financial
Services, Attention: Prospectus Department, 1155 Long Island
Avenue, Edgewood, NY 11717, Telephone: 631-274-2806, Fax:
631-254-7140; or Piper Jaffray & Co., 800 Nicollet Mall, Suite
1000, Minneapolis, MN 55402, Telephone: 800-747-3924, Email:
prospectus@pjc.com.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy these securities, nor shall there
be any sale of these securities in any state or other jurisdiction
in which such offer, solicitation or sale would be unlawful prior
to the registration or qualification under the securities laws of
any such state or other jurisdiction.
About Adamas Pharmaceuticals
Adamas Pharmaceuticals, Inc. is a biopharmaceutical company
committed to developing product candidates for the treatment of
chronic disorders of the central nervous system.
Forward-Looking Statements
This announcement contains forward-looking statements, including
statements relating to Adamas’ expectations regarding the
completion, timing and size of the proposed public offering. These
statements are subject to significant risks and uncertainties,
actual results could differ materially from those projected and
Adamas cautions investors not to place undue reliance on the
forward-looking statements contained in this release. These risks
and uncertainties include, without limitation, risks and
uncertainties related to market conditions and satisfaction of
customary closing conditions related to the public offering. There
can be no assurance that Adamas will be able to complete the public
offering on the anticipated terms, or at all. Risks and
uncertainties relating to Adamas and its business can be found in
the “Risk Factors” section of Adamas’ Form 10-Q, filed with the SEC
on November 12, 2015, and in the preliminary prospectus supplement
related to the proposed offering to be filed with the SEC. Adamas
undertakes no duty or obligation to update any forward-looking
statements contained in this release as a result of new
information, future events or changes in Adamas’ expectations.
For questions, please contact:
Julie Wood
Corporate Communications & Investor Relations
Adamas Pharmaceuticals, Inc.
Phone: 510-450-3528
Adamas Pharmaceuticals (NASDAQ:ADMS)
Historical Stock Chart
From May 2024 to Jun 2024
Adamas Pharmaceuticals (NASDAQ:ADMS)
Historical Stock Chart
From Jun 2023 to Jun 2024